2.43
Erasca Inc stock is traded at $2.43, with a volume of 4.90M.
It is down -2.02% in the last 24 hours and up +56.77% over the past month.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
See More
Previous Close:
$2.48
Open:
$2.52
24h Volume:
4.90M
Relative Volume:
3.78
Market Cap:
$689.32M
Revenue:
-
Net Income/Loss:
$-125.04M
P/E Ratio:
-2.9634
EPS:
-0.82
Net Cash Flow:
$-122.99M
1W Performance:
+9.95%
1M Performance:
+56.77%
6M Performance:
+129.25%
1Y Performance:
-3.57%
Erasca Inc Stock (ERAS) Company Profile
Name
Erasca Inc
Sector
Industry
Phone
(858) 465-6511
Address
3115 MERRYFIELD ROW, SAN DIEGO
Compare ERAS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ERAS
Erasca Inc
|
2.43 | 703.50M | 0 | -125.04M | -122.99M | -0.82 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
421.15 | 105.19B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
450.68 | 60.24B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
563.86 | 61.82B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
798.94 | 49.09B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
351.09 | 37.52B | 4.56B | -176.77M | 225.30M | -1.7177 |
Erasca Inc Stock (ERAS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-03-25 | Downgrade | BofA Securities | Buy → Underperform |
Aug-18-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Mar-26-25 | Initiated | Raymond James | Outperform |
Nov-18-24 | Initiated | Jefferies | Buy |
Mar-11-24 | Initiated | CapitalOne | Overweight |
Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
Oct-11-23 | Initiated | H.C. Wainwright | Buy |
Mar-30-23 | Initiated | Mizuho | Buy |
Feb-24-23 | Initiated | Goldman | Buy |
Feb-03-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
View All
Erasca Inc Stock (ERAS) Latest News
Will Erasca Inc. price bounce be sustainableIndex Update & Accurate Entry/Exit Alerts - newser.com
Why Erasca Inc. stock remains on buy lists2025 Year in Review & Fast Gain Stock Trading Tips - newser.com
Will Erasca Inc. stock benefit from upcoming earnings reportsJuly 2025 Short Interest & Low Risk High Reward Ideas - newser.com
Can swing trading help recover from Erasca Inc. losses2025 Price Momentum & Community Driven Trade Alerts - newser.com
Why retail investors favor Erasca Inc. stockMarket Performance Summary & Weekly High Conviction Ideas - newser.com
Erasca: Hype Building Into The End Of The Year (Rating Downgrade) (NASDAQ:ERAS) - Seeking Alpha
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
Why Concorde International Group Shares Are Trading Higher By 55%; Here Are 20 Stocks Moving Premarket - Benzinga
What drives Erasca Inc stock priceMarket Rumors and News & High Return Stock Ideas - earlytimes.in
Erasca Inc Stock Analysis and ForecastBreakout Stock Watch & Interactive Charts for Smarter Trading - earlytimes.in
Erasca, Inc. (NASDAQ:ERAS) Receives $3.71 Consensus PT from Analysts - Defense World
Key resistance and support levels for Erasca Inc.Weekly Profit Summary & AI Driven Stock Price Forecasts - newser.com
Wall Street Zen Upgrades Erasca (NASDAQ:ERAS) to Hold - Defense World
Erasca Inc Stock (ERAS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):